BlackWillow Research
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
Published August 20, 2026
Investment Memorandum | Preliminary IC Review | August 2026
1. Executive Summary
Neurocrine has evolved from a largely single-product neuroscience company into a more diversified commercial biopharma platform anchored by INGREZZA, CRENESSITY and VYKAT XR, with a substantial late-stage pipeline behind them. The 2026 operating trajectory is strong. Q2 revenue reached $959M, up 39% YoY. INGREZZA grew 15% to $716M, CRENESSITY grew 247% to $184M, and acquired VYKAT XR contributed $54M for the partial quarter following the May acquisition of Soleno Therapeutics. Management also increased 2026 INGREZZA sales guidance to $2.825B–$2.875B. This is important because the historical bear case on Neurocrine has been concentration. In 2025 INGREZZA generated $2.51B of the company's $2.86B revenue, while CRENESSITY contributed $301M in its first full year. The emergence of CRENESSITY and VYKAT XR, combined with multiple Phase 3 psychiatry programs, begins to materially weaken that concentration argument.
Our screen also shows a strong quality-growth setup:
| Metric | Value |
|---|---|
| revenue growth | ~21.4% |
| three-year revenue CAGR | ~24.3% |
| EPS growth | ~41.9% |
| three-year EPS CAGR | ~44.1% |
| FCF growth | ~34.4% |
| three-year FCF CAGR | ~32.4% |
| gross margin | ~98% |
| operating margin | ~22% |
| net margin | ~27% |
| ROIC | ~13% |
| fundamental score | ~69.1 |
| valuation score | ~61.1 |
| final quantitative score | ~63.5. |
At the reference price, NBIX trades at approximately 13.0x forward earnings, 17.4x EV/EBITDA and 4.7x EV/revenue, with a forward earnings yield of roughly 7.7%. That makes NBIX much closer to the kind of quality + growth + value mismatch we should be trying to discover.
2. Why NBIX Emerged From BlackWillow
The score profile is unusually balanced.
| BlackWillow dimension | Score / percentile |
|---|---|
| Fundamental score | 69.1 |
| Industry fundamental score | 69.6 |
| Sector fundamental score | 68.9 |
| Universe fundamental score | 67.0 |
| Growth, industry | 76.0 |
| Profitability, industry | 82.3 |
| Capital efficiency, industry | 71.0 |
| Cash quality, industry | 69.5 |
| Balance sheet, industry | 70.1 |
| Valuation score | 61.1 |
| Momentum score | 50.4 |
| Final quantitative score | 63.5 |
NBIX demonstrates strong growth, strong margins, improving diversification and a considerably more reasonable multiple.
3. Business Model
Neurocrine develops and commercializes therapies primarily across neurology, psychiatry, endocrinology, and immunology. INGREZZA is approved for tardive dyskinesia and chorea associated with Huntington's disease. It remains the economic engine.
Sales progressed from:
| Year | INGREZZA sales |
|---|---|
| 2023 | $1.84B |
| 2024 | $2.31B |
| 2025 | $2.51B |
Q2 2026 sales reached $716M, +15% YoY, driven by double-digit prescription growth and record new prescriptions. Management subsequently raised full-year guidance from $2.7–2.8B to $2.825–2.875B. The franchise is therefore mature in scale but not yet mature in growth.
4. CRENESSITY: The First Diversification Proof Point
CRENESSITY may be the most important development in the current investment thesis. It was launched in December 2024 as a first-in-class treatment for classic congenital adrenal hyperplasia.
Sales reached:
| Metric | Value |
|---|---|
| FY2025 | $301M |
| Q1 2026 | $153M |
| Q2 2026. | $184M |
Q2 growth was 247% YoY, although the prior-year base was still early in launch. The more useful observation is sequential performance with Q1 = $153M and Q2 = $184M. That is roughly 20% sequential growth. Neurocrine also reported approximately 80% reimbursement for dispensed prescriptions, suggesting payer access is becoming established. This changes the corporate story. Before CRENESSITY, investors could reasonably argue: NBIX = INGREZZA. That statement is increasingly wrong.
5. VYKAT XR and the Soleno Acquisition
In May 2026 Neurocrine completed its acquisition of Soleno Therapeutics for approximately $2.9B, adding VYKAT XR for hyperphagia in Prader-Willi syndrome. VYKAT generated $54M of reported Q2 sales from the May 18 closing date. On a full-quarter pro forma basis, sales would have been approximately $94M. That is already a meaningful commercial contribution. Annualizing $94M mechanically would imply roughly $376M, although that should not be treated as guidance because the product is still early in its commercial trajectory. The acquisition accomplishes three things: adds another first-in-class rare-disease commercial asset; reduces dependence on INGREZZA; gives Neurocrine another growth platform with a distinct patient population. The price paid was substantial, however. Cash and marketable securities fell from approximately $2.54B at year-end 2025 to $482M at June 30, 2026, primarily reflecting the acquisition. This is therefore a strategic diversification move, not free optionality.
6. Commercial Diversification Is Now Visible
Q2 product revenue composition illustrates the shift:
| Product | Q2 2026 sales | Share of major-product revenue |
|---|---|---|
| INGREZZA | $716M | ~75% |
| CRENESSITY | $184M | ~19% |
| VYKAT XR | $54M reported | ~6% |
That remains concentrated, but far less so than even one year ago. Using VYKAT's $94M pro forma full-quarter result, INGREZZA would represent closer to roughly 72% of commercial revenue. The market may still anchor on the historic concentration profile while the actual revenue mix is changing rather quickly.
7. Historical Financial Development
Company-reported total revenue progressed:
2023: $1.89B
2024: $2.36B
2025: $2.86B.
That represents approximately 23% annualized growth across the period.
BlackWillow's standardized financial series shows:
| Metric | NBIX |
|---|---|
| Revenue growth YoY | 21.4% |
| Revenue 3y CAGR | 24.3% |
| Gross profit growth | 21.0% |
| Operating income growth | 9.2% |
| EBITDA growth | 4.2% |
| EPS growth | 41.9% |
| EPS 3y CAGR | 44.1% |
| OCF growth | 31.5% |
| FCF growth | 34.4% |
| FCF 3y CAGR | 32.4% |
The mix is interesting. Revenue, EPS and cash flow growth are excellent, while operating-income and EBITDA growth were temporarily less spectacular because Neurocrine is deliberately increasing R&D and commercial investment. That distinction matters.
8. Profitability and Reinvestment
BlackWillow calculates:
| Metric | NBIX |
|---|---|
| Gross margin | 98.2% |
| Operating margin | 22.3% |
| EBITDA margin | 23.3% |
| Net margin | 27.4% |
| OCF margin | 27.4% |
| FCF margin | 26.2% |
| ROIC | 13.3% |
| ROCE | 16.4% |
| ROA | 10.3% |
| ROE | 14.7% |
The company is not maximizing near-term operating margin. In 2025, R&D expense was approximately $1.02B, up from $731M; SG&A was approximately $1.16B, up from $1.01B. For 2026, R&D guidance was subsequently increased to $1.275–1.325B GAAP, while SG&A guidance rose to $1.575–1.600B, partly reflecting the Soleno transaction and continued commercial expansion. The critical interpretation is therefore is margin restraint today partly reflects deliberate reinvestment into additional commercial franchises and late-stage pipeline assets. That is potentially attractive if those investments produce the intended second and third growth engines.
9. Q2 2026: Stronger Than the Historical Screen
The latest quarter is stronger than the FY2025 ratios alone imply.
Q2 2026:
| Metric | Value |
|---|---|
| revenue | $959M, +39% |
| INGREZZA | $716M, +15% |
| CRENESSITY | $184M, +247% |
| VYKAT XR | $54M partial-quarter |
| GAAP net income | $144M, +33% |
| non-GAAP net income | $297M, +79% |
| non-GAAP diluted EPS | $2.85 vs $1.65. |
This is a significant operating inflection. Importantly, the 39% revenue growth is not purely organic because VYKAT entered through acquisition.
But even excluding VYKAT:
| Metric | Value |
|---|---|
| $959M − | $54M = ~$905M |
versus $688M a year earlier, implying roughly 32% growth before the acquired contribution. That is still extremely strong.
10. The Pipeline
NBIX becomes more interesting when viewed as a cash-generating commercial company funding a high-value pipeline, rather than a speculative biotech waiting for one clinical readout. The company highlights multiple late-stage programs, including: osavampator in major depressive disorder, direclidine in schizophrenia, additional muscarinic programs, further CRF-related endocrine/metabolic programs. Management expects important Phase 3 readouts in 2027 for osavampator and direclidine. These programs matter because psychiatry represents a substantially larger commercial market than many of Neurocrine's current rare-disease indications. If one succeeds, the company's long-run earnings profile could change materially. If both fail, NBIX still retains three commercial assets. That asymmetry is considerably more favorable than in a pre-revenue biotech.
11. The Variant Perception
What the market historically saw: INGREZZA plus pipeline. That created understandable concern about product concentration and eventual franchise maturity.
What BlackWillow sees developing: INGREZZA funding a portfolio transition toward a diversified neuroscience/endocrine commercial platform.
The evidence: INGREZZA still growing double digits; CRENESSITY already approaching a significant commercial scale; VYKAT adding another rare-disease franchise; substantial late-stage psychiatry pipeline; internal cash generation funding R&D rather than depending on equity markets. This is a far more robust corporate structure than a typical mid-cap biotechnology company.
12. Valuation
| Metric | NBIX |
|---|---|
| Price | $155.54 |
| Market cap | $15.81B |
| Enterprise value | $15.88B |
| Trailing P/E | 22.6x |
| Forward P/E | 13.0x |
| PEG | 0.45x |
| Price / Book | 4.3x |
| Price / Sales | 4.7x |
| EV / EBITDA | 17.4x |
| EV / Revenue | 4.7x |
| FCF yield | 4.0% |
| OCF yield | 5.7% |
| Forward earnings yield | 7.7% |
| Forward EPS growth | ~73.5% |
The forward EPS growth figure should be treated cautiously because consensus periods can introduce distortions, but the broader point stands: NBIX trades at a much less demanding earnings multiple than the first two finalists despite comparable or better near-term operating growth.
13. Why the Multiple May Be Lower
There are legitimate reasons. The market must discount pharmaceutical patent life; dependence on INGREZZA; clinical-trial uncertainty; acquisition integration; drug-pricing policy; competition; potential future generic entry. So this is not a free lunch. But those risks are at least visible and analyzable, whereas the diversification trajectory is moving in the opposite direction. That creates the possible mismatch.
14. Balance Sheet After Soleno
This is the part of the screen requiring reinterpretation. At year-end 2025 Neurocrine had approximately $2.54B in cash and investments. Following the $2.9B Soleno acquisition, Q2 cash and marketable securities fell to approximately $482M. Neurocrine also established a $1B revolving credit facility, which remained undrawn at June 30. Therefore, older balance-sheet ratios in the historical BlackWillow screen overstate the company's current net-cash strength. This is exactly the sort of post-screen adjustment institutional diligence should make. The balance sheet is now characterized as adequate and supported by strong cash generation, but no longer exceptionally cash-rich.
15. Scenario Framework
A simple earnings-based framework is more natural here than EV/revenue.
Using the reference price of $155.54:
| Scenario | Normalized forward EPS | Multiple | Implied value | Approx. return |
|---|---|---|---|---|
| Bear | $9.00 | 13x | $117 | -25% |
| Base | $12.50 | 17x | $213 | +37% |
| Bull | $15.00 | 20x | $300 | +93% |
These are BlackWillow scenario assumptions, not management guidance.
Bear case: INGREZZA growth falls quickly; CRENESSITY slows; VYKAT integration disappoints; late-stage psychiatry pipeline fails; valuation remains compressed.
Base case: INGREZZA grows high-single/low-double digits; CRENESSITY continues scaling; VYKAT becomes a meaningful third franchise; operating leverage improves after integration spending; pipeline retains optionality.
Bull case: commercial diversification performs above expectations; one major psychiatry program succeeds; market begins valuing NBIX as a multi-franchise biopharma platform rather than a one-product company. The base/bull case is therefore driven by portfolio evolution, not multiple expansion alone.
16. Catalysts
Continued INGREZZA guidance revisions: Management has already increased 2026 guidance to $2.825–2.875B. Further prescription momentum would reinforce franchise durability.
CRENESSITY trajectory: Sequential sales progression is one of the cleanest indicators of whether diversification is working.
VYKAT XR scaling: Q2 pro-forma sales of ~$94M establish a meaningful starting point. The next several quarters will show whether Neurocrine can accelerate uptake after integration.
2027 psychiatry readouts: Phase 3 data for osavampator and direclidine could materially change long-term TAM and earnings expectations.
Operating leverage: The market may reward the company if commercial and acquisition spending begins normalizing while revenue continues scaling.
17. Principal Risks
| Risk | Probability | Impact | Indicator |
|---|---|---|---|
| INGREZZA growth slows faster than expected | Medium | High | prescriptions, guidance |
| CRENESSITY uptake plateaus | Medium | Medium/High | sequential sales |
| VYKAT acquisition underperforms | Medium | High | product sales, integration costs |
| Phase 3 pipeline failures | Medium/High | High | 2027 readouts |
| Drug-pricing/reimbursement pressure | Medium | High | gross-to-net trends |
| Generic/patent risk | Medium term | High | IP milestones |
| SG&A/R&D remain elevated | Medium | Medium | margin progression |
| Balance-sheet flexibility reduced post-acquisition | Medium | Medium | FCF/debt usage |
The most important current risk remains INGREZZA concentration. Despite diversification, INGREZZA still generated approximately 75% of major-product Q2 sales. We should not pretend the transition is complete.
18. Thesis Breakers
Reassess the investment if:
INGREZZA sales growth falls below mid-single digits materially earlier than expected;
CRENESSITY sequential growth stalls for multiple quarters;
VYKAT XR sales fail to approach the commercial trajectory implied by the acquired asset's pre-deal performance;
commercial diversification fails to reduce INGREZZA below ~65–70% of product revenue over the next few years;
both major psychiatry Phase 3 programs fail;
operating expenses grow persistently faster than product sales after integration;
FCF conversion deteriorates substantially;
acquisition-related leverage rises without corresponding earnings growth.
Those are testable conditions.
19. Market Confirmation
NBIX has a much less dramatic price profile than many growth candidates.
Our snapshot shows:
12-month momentum around +15.8%
approximately 7% below the 50-day-relative measure
about 5.8% above its 200-day comparison
roughly 16% below the 52-week high
average daily dollar volume of approximately $196M.
That generates only a ~50 momentum score.
The operating performance is much stronger than the price momentum. In other words, the stock does not appear to be shortlisted because the tape is doing all the work.
20. BlackWillow View
What we like:
strong organic revenue growth;
accelerating diversification;
INGREZZA still healthy rather than ex-growth;
CRENESSITY already commercially significant;
VYKAT adds a third franchise;
profitable existing business funds pipeline development;
2027 clinical optionality;
substantially better valuation than IDCC/RMBS;
institutionally liquid without being a household-name stock.
What concerns us:
INGREZZA remains dominant;
Soleno consumed much of the company's former cash cushion;
R&D and SG&A spending are escalating;
pipeline value is inherently probabilistic;
acquisition integration adds another execution variable.